Our preparation of the mitomycin-C includes mixing the drug with a sterile water diluent to achieve a starting concentration of 0.2 mg/ml. This is then diluted further with 2% lidocaine—the same lidocaine we would use in a retrobulbar block.

Each vial of Mitosol® contains 0.2 mg of mitomycin and mannitol in a 1:2 concentration ratio. To reconstitute, add 1 mL of Sterile Water for Injection, then shake to dissolve. If product does not dissolve immediately, allow to stand at room temperature until the product dissolves into solution.

MMC 0.02% solution was prepared by adding 10 ml of sterile distilled water to 2 mg MMC. The solution was refrigerated and protected from light.

Mitomycin-C should be reconstituted in sterile water at neutral pH, the drug is inactivated in an acidic solution. The drug should be stored under refrigeration to preserve its potency under these conditions, Mitomycin-C is potent for a period of two weeks [3]. The drug is available in a vial (2mg/ml and 10mg/ml).

Mitomycin-C and MTC are other names for Mitomycin. In some cases, health care professionals may use the trade name Mutamycin or other names Mitomycin-C and MTC when referring to the generic drug name Mitomycin. Drug type: Mitomycin-C is an anti-cancer (“antineoplastic” or “cytotoxic”) chemotherapy drug.

Mitomycin C is a powerful agent which prevents scarring by inhibiting the multiplication of cells which produce scar tissue. This review asks whether there is evidence that its use during the initial stages of surgery to prevent the excessive conjunctival scarring reduces the risk of failure of the operation.

The overall analysis revealed a significant benefit of BCG compared with mitomycin C in terms of 5-year PFS rate (odds ratio, 0.53; 95% confidence interval, 0.38–0.75; P<0.001), indicating that BCG was superior to mitomycin C therapy in patients with non-muscle invasive bladder cancer following transurethral resection.

Trabeculectomy with mitomycin C remains the standard surgery for glaucoma. This surgery involves creating a door in the eye wall in order to improve fluid outflow and decrease intraocular pressure. However, success rates range from 70% to 90% depending on the criteria used and tend to decrease with time.

5-FU is widely used in ophthalmology for inhibition of postoperative corneal scarring and scleral bleb fibrosis. It is used postoperatively in refractive procedures to decrease the risk of corneal haze [2, 3].

MMC is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of MMC in ethanol is approximately 0.1 mg/ml and approximately 20 mg/ml in DMSO and DMF.

Mitomycin is a type of antibiotic that is only used in cancer chemotherapy. It slows or stops the growth of cancer cells in your body.

Mitomycin ophthalmic is a liquid medicine that is applied first to a tray of tiny sponges. The sponges will soak in the mitomycin for at least 60 minutes. Once the sponges are saturated with mitomycin, your surgeon will place the sponges directly onto your eye.

Our preparation of the mitomycin-C includes mixing the drug with a sterile water diluent to achieve a starting concentration of 0.2 mg/ml. This is then diluted further with 2% lidocaine—the same lidocaine we would use in a retrobulbar block.

The most commonly used method of applying mitomycin-C during glaucoma surgery is to soak a Weck-Cel sponge in a solution of the drug and then apply the sponge to the ocular tissues for a few minutes.

Mitomycin C (MMC) is a cytostatic agent topically used in conjunctival neoplasms, secondary to glaucoma filtering, pterygium, and strabismus surgery to increase the success rate. The topical formulation of MMC for ocular use is always extemporaneously prepared.